Grant Award Details
Human Pancreatic Cancer Stem Cells: Developing a Novel Drug for Cancer Eradication
Grant Application Details
- Human Pancreatic Cancer Stem Cells: Developing a Novel Drug for Cancer Eradication
We will use human pancreatic cancer (PC) stem cells to show 1 inhibits proliferation, self-renewal and cell viability. This paradigm is transformational for anti-cancer drug discovery for patients.
Pancreatic cancer (PC) kills >40,000/yr in the US. PC is a major unmet medical need. Use of PC stem cells in development of 1 will usher in a new paradigm. 1 may be of great utility with other drugs.
Major Proposed Activities
- Show 1 potently and selectively reduces self-renewal capacity and cell viability of a human pancreatic cancer stem cell and compare the result with a normal pancreatic cancer cell.
- Show 1 induces apoptosis of a human pancreatic cancer stem cell line via the intrinsic induced cell death (or apoptosis) pathway.
- Show effectiveness of 1 as an inhibitor of the KRAS-NF-κB signaling pathway as a mechanism to eradicate human pancreatic cancer stem cell progression relevant to human patients.
- Summarize the results in a pre-IND report and contact the U.S. FDA. Apply for financial support to do additional IND-enabling studies.
We will develop a new pancreatic cancer (PC) therapy using PC cancer stem cells. In California, the incidence of PC death is ~5,000/yr. PC incidence is increasing in CA & will be 20% greater in 2020. Therapy for PC is limited to surgery. Combination of chemotherapy & radiation are ineffective. Thus, PC is a major unmet medical need. Successful completion of this work will provide CA citizens much needed advances in PC health technology & improvement in health care & effective anti-cancer drugs.
- Sci Rep (2020) PAWI-2 overcomes tumor stemness and drug resistance via cell cycle arrest in integrin beta3-KRAS-dependent pancreatic cancer stem cells. (PubMed: 32514015)
- Am J Cancer Res (2019) Inhibition of invasive pancreatic cancer: restoring cell apoptosis by activating mitochondrial p53. (PubMed: 30906636)